Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.54 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | BLVRB | P30043 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.50 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8868737 | 0.95 | XDH (0.55) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL8867957 | 0.91 | XDH (0.51) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL8867804 | 0.89 | XDH (0.67) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL8866949 | 0.88 | CDC7 (0.52) | XDHCDC7DBF4LMNA | |
| SCHEMBL8868456 | 0.86 | CDC7 (0.50) | CDC7DBF4LMNA | |
| SCHEMBL8867675 | 0.86 | CDC7 (0.50) | CDC7DBF4LMNA | |
| SCHEMBL8868452 | 0.86 | CDC7 (0.49) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL459923 | 0.85 | XDH (0.58) | XDHTARBP2ABCC4ABCB11PGR | |
| SCHEMBL8868127 | 0.84 | CDC7 (0.54) | CDC7DBF4LMNA | |
| SCHEMBL455907 | 0.84 | XDH (0.57) | XDHTARBP2ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320474-B | Preparation method of febuxostat | 昆明源瑞制药有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-106661014-B | Azole benzene derivative and crystal thereof | 帝人制药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| US-10179780-B2 | Azole benzene derivative and crystalline form thereof | TEIJIN PHARMA LIMITED (JP) | 2019-01-15 | — | — | US | disclosed |
| EP-3176166-B1 | AZOLE BENZENE DERIVATIVE AND CRYSTAL THEREOF | TEIJIN PHARMA LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20170247364-A1 | AZOLE BENZENE DERIVATIVE AND CRYSTALLINE FORM THEREOF | TEIJIN PHARMA LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| EP-3176166-A1 | AZOLE BENZENE DERIVATIVE AND CRYSTAL THEREOF | Teijin Pharma Limited (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| CN-102936230-A | New preparation method of febuxostat | Ge changle | 2013-02-20 | — | — | CN | disclosed |
| CN-102002017-B | Method for preparing febuxostat intermediate | BEIJING SECOND PHARMACEUTICAL CO LTD | 2012-09-26 | — | — | CN | disclosed |
| WO-2012073259-A1 | NOVEL PROCESS FOR THE PREPARATION OF FEBUXOSTAT | INDOCO REMEDIES LIMITED (IN) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012073259-A1 | NOVEL PROCESS FOR THE PREPARATION OF FEBUXOSTAT | INDOCO REMEDIES LIMITED (IN) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012032528-A2 | IMPROVED PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | NATCO PHARMA LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| US-5614520-A | 2-arylthiazole derivatives and pharmaceutical composition thereof | TEIJIN LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0513379-B1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0513379-A1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247364-A1 | AZOLE BENZENE DERIVATIVE AND CRYSTALLINE FORM THEREOF | XDH, NOD1, NLRP3 | XDH 1/4885TARBP2 2820/4885ABCC4 358/4885 |
| US-20130172571-A1 | PROCESS TO PREPARE ETHYL 4-METHYL-2-(4-(2-METHYLPROPYLOXY)-3-CYANOPHENYL)-5-THIAZOLECARBOXYLATE | FIP1L1, UMPS, UBXN4 | XDH 55/4885TARBP2 2807/4885ABCC4 1420/4885 |
| US-10179780-B2 | Azole benzene derivative and crystalline form thereof | XDH, NOD1, NLRP3 | XDH 1/4885TARBP2 2820/4885ABCC4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.